Mexico Arturo Rodriguez, CEO of Infinite Clinical Research, discusses the current state of clinical trials in Mexico and highlights the country’s unique advantages, such as a diverse population with experienced medical professionals and top-notch medical facilities. He addresses the challenges of streamlining regulatory processes and the need for improvements to attract…
Switzerland Kari Sarvanto outlines his journey from leading PRIMEX to establishing CRAB, a preclinical oncology company focused on non-toxic cancer treatments. Sarvanto highlights his strategic leadership background, the innovative approach of targeting metabolic dysfunctions in cancer, and the promising progress of their lead drug, CRB091, particularly in treating aggressive cancers like…
USA In a country characterised by its racial and ethnic diversity, but where less than 5 percent of clinical trial data includes racial and ethnic factors, clinical trial diversity has become a key issue for the US FDA. Drug and medical device makers recognise the importance of diversity but find their…
Hong Kong Hong Kong has grand plans to become one of Asia’s leading clinical trial hubs. Important regulatory upgrades and increased integration with mainland China via the Greater Bay Area initiative – including a new dedicated GBA Clinical Trial Institute at the Hong Kong/mainland border – mean that this is not just…
Switzerland Daniel Weber of Boehringer Ingelheim Switzerland explores the company’s strategic initiatives and focus on innovation within the Swiss healthcare system. Weber emphasizes Boehringer Ingelheim’s long-term vision of transforming lives, its commitment to early diagnosis, and its expanding role in digital health. Our purpose and strong pipeline are what truly…
Switzerland Incyte’s Jonathan Dickinson discusses the company’s mission to address unmet medical needs in oncology and autoimmune diseases while expanding its footprint across Europe. He highlights the strategic role of Incyte’s internal research, clinical trials, and recent product launches, along with their ambitions to double European revenues in the coming years.…
Switzerland Johnson & Johnson Innovative Medicine’s Max Pahlow discusses how the company’s commitment to innovation and patient care drives its success in Switzerland. He highlights the importance of advancing clinical trials, digitalization, and modernizing the pricing and reimbursement system to maintain Switzerland’s competitive edge in healthcare. Switzerland isn’t a lucky…
Switzerland Dr René Buholzer, CEO of Interpharma, covers Switzerland’s healthcare advancements, regulatory progress, and the challenges in drug access and digitalization over the past three years. Emphasising collaboration and innovation, Interpharma’s ‘Pharma Strategy 2030’ aims to solidify Switzerland’s leadership in R&D and healthcare sustainability. Our vision is not just about…
Global Contract research organisations (CROs) have proven to be increasingly vital partners for the global biopharmaceutical industry guaranteeing efficient and compliant clinical trials that help to advance their candidates towards regulatory approvals. CROs have also demonstrated their ability to adapt to the industry’s changing needs by enlarging their geographical reach and…
Mexico Valney Suzuki highlights his focus on expanding access to Novo Nordisk’s innovations in Mexico, especially for vulnerable populations; the importance of ethical usage of the company’s groundbreaking semaglutide-based treatments for diabetes and obesity; and Mexico’s crucial role in Novo Nordisk’s global operations, not just as a market but also in…
Hong Kong Hong Kong needs to capitalise on its strong fundamentals to establish itself as a clinical research hotspot within APAC and support its transition into China’s innovation and technology hub. Does a new one-stop-shop for clinical trials across the Greater Bay Area hold the key? Clinical trial numbers are skyrocketing…
Hong Kong Billed as China’s attempt to create an economic powerhouse to rival Silicon Valley, ‘The Greater Bay Area’ is a mega-region that includes nine cities in Guangdong province plus the Special Administrative Regions of Hong Kong and Macau. Since its launch in 2017, the GBA has worked to integrate these cities…
See our Cookie Privacy Policy Here